Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
Patel V, Qin Q, Wang B, Gogerly-Moragoda M, Mellgard G, Zhong X, Parikh A, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Clinical Oncology 2020, 38: e15068-e15068. DOI: 10.1200/jco.2020.38.15_suppl.e15068.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsDisease control rateClinical activity of immune checkpoint inhibitorsActivity of immune checkpoint inhibitorsAdvanced solid tumorsBeta blockersSolid tumorsCheckpoint inhibitorsDose of immune checkpoint inhibitorsCD8+ T cell activationClinical activityImproved disease control rateClinical outcomes of patientsAntitumor immune activityPharmacological beta-blockadeRadiographic complete responseEffects of beta blockersECOG performance statusLocation of metastasesOutcomes of patientsBeta-blocker useT cell activationInhibited tumor growthMultivariate logistic regression modelStable disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply